The messenger RNA (mRNA) market is rapidly expanding, projected to grow to $20.99 billion by 2035, fueled by the success of mRNA-based vaccines during the COVID-19 pandemic and ongoing innovations in therapeutic applications. The market is particularly strong in infectious disease management, with North America leading in regulatory frameworks and manufacturing capabilities. Recent developments include Moderna’s updated COVID-19 vaccine, Pfizer’s approval for at-risk populations, and new partnerships aimed at enhancing mRNA technology for respiratory diseases. Nevertheless, challenges like manufacturing complexity and cold-chain logistics persist, alongside opportunities for advancements in gene editing and personalized medicine.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.globenewswire.com/news-release/2026/04/07/3269488/28124/en/messenger-rna-mrna-market-projected-to-reach-20-99-billion-by-2035-moderna-pfizer-and-others-propel-mrna-expansion-into-new-therapeutic-areas.html
